Jefferies raises Tarsus Pharmaceuticals price target to $105, keeps Buy
Jefferies maintained a Buy rating on Tarsus Pharmaceuticals while raising its price target to $105.00 per share from $88.00,
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.